SINTX Technologies and Iwatani Group Announce Agreement to Develop Antipathogenic Surfaces to Help Prevent Spread of the Comm...
November 13 2020 - 9:00AM
SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”)
(www.sintx.com), an original equipment manufacturer (OEM) of
silicon nitride ceramic for medical and non-medical applications,
and Iwatani Corporation of America (ICA), a wholly-owned subsidiary
of Iwatani Corporation, announced today that they have entered into
a joint development agreement.
The goal of this agreement is to incorporate
SINTX AP2 silicon nitride powder into polymer materials. These
materials will become safe and effective surfaces for IT devices
such as cases for cell phones and tablets that are touched
frequently. SINTX and Iwatani aim to create surfaces that resist
bacteria and viruses. The successful development of these products
may help prevent and reduce the spread of respiratory diseases like
SARS-CoV-2, Influenza A, and H1N1 by inactivating viruses and
bacteria on the polymer surfaces.
“We are pleased to enter this joint development
agreement with Iwatani, toward developing new products that
leverage the intrinsic antipathogenic properties of silicon
nitride,” said Dr. Bal. “The collaboration with Iwatani is intended
to directly apply our material science expertise toward new product
development and revenues, a very significant and exciting move for
SINTX.”
SINTX and Iwatani intend to capitalize on recent
and promising data demonstrating the potential of SINTX AP2silicon
nitride powder to inactivate the SARS-CoV-2 virus that is
responsible for the global COVID-19 pandemic. Studies showing the
rapid inactivation of SARS-CoV-2 by SINTX’s silicon nitride are the
latest in a series of papers showing similar activity of silicon
nitride against a variety of bacteria and viral strains. SINTX and
Iwatani plan to jointly fund collaborative product development
activities in Salt Lake City, Utah, and Japan with the support of
external laboratories as well.
SINTX notes they are working diligently to
incorporate silicon nitride into several products such as masks and
consumer electronic products and other surfaces that will help
inactivate respiratory pathogens. The joint development agreement
between Iwatani and SINTX will help SINTX advance their materials
science, while external partners like Iwatani develop commercial
products that can help protect the worldwide community against
viral diseases.
About SINTX Technologies, Inc.
SINTX Technologies is an OEM ceramics company
that develops and commercializes silicon nitride for medical and
non-medical applications. The core strength of SINTX Technologies
is the manufacturing, research, and development of silicon nitride
ceramics for external partners. The Company presently manufactures
silicon nitride powders and components in its FDA registered,
AS9100D certified, and ISO 13485:2016 certified manufacturing
facility.
For more information on SINTX Technologies or its silicon
nitride material platform, please visit www.sintx.com.
Forward-Looking Statements
This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995 (PSLRA) that are subject to a number of risks
and uncertainties. Risks and uncertainties that may cause such
differences include, among other things, SINTX’s ability to
complete its obligations under the agreement; the collaboration
with Iwatani may not result in the development of any products;
that SINTX has not as yet developed any products with antiviral
properties which incorporate the use of silicon nitride; products
developed under the joint development agreement may not be
effective against the SARS-CoV-2 virus; incorporation of silicon
nitride into personal protective equipment may not be safe or
effective; volatility in the price of SINTX’s common stock; the
uncertainties inherent in new product development, including the
cost and time required to commercialize such product(s); market
acceptance of our products once commercialized; SINTX’s ability to
raise additional funding and other competitive developments.
Readers are cautioned not to place undue reliance on the
forward-looking statements, which speak only as of the date on
which they are made and reflect management’s current estimates,
projections, expectations, and beliefs. There can be no assurance
that any of the anticipated results will occur on a timely basis or
at all due to certain risks and uncertainties, a discussion of
which can be found in SINTX’s Risk Factors disclosure in its Annual
Report on Form 10-K, filed with the Securities and Exchange
Commission (SEC) on March 26, 2020, and in SINTX’s other filings
with the SEC. SINTX disclaims any obligation to update any
forward-looking statements. SINTX undertakes no obligation to
publicly revise or update the forward-looking statements to reflect
events or circumstances that arise after the date of this
report.
Business Inquiries for SINTX:SINTX
Technologies801.839.3502IR@sintx.com
Media Inquiries for SINTX: Amanda Barry
Associate Director, Content and PR The Summit Group
abarry@summitslc.com
SiNtx Technologies (NASDAQ:SINT)
Historical Stock Chart
From Mar 2024 to Apr 2024
SiNtx Technologies (NASDAQ:SINT)
Historical Stock Chart
From Apr 2023 to Apr 2024